AIMS: To characterize the effect of sacral neuromodulation (SNM) on urethral neuromuscular function. METHODS: Following IRB approval, women with refractory overactive bladder (OAB) underwent standardized urethral testing prior to and after Stage 1 SNM implantation. Periurethral sensation was measured using current perception thresholds (CPT). Striated urethral sphincter activity was quantified using concentric needle electromyography (CNE) and Multi-Motor Unit Action Potential (MUP) analysis software. Nonparametric analyses were used to characterize pre/post changes with intervention. Baseline CPT and CNE findings were compared between SNM responders and non-responders. RESULTS: Twenty-seven women were enrolled in this pilot study with a mean age of 61 ± 13 years. Twenty of 26 women (76.9%) responded to SNM and went to Stage 2 permanent implantation. Four (14.8%) withdrew after Stage 1 implantation; three of the four withdrawals had not had therapeutic responses to SNM. CPT and CNE parameters did not significantly differ from baseline 2 weeks after SNM. Pre-SNM urethral sensation was not significantly different between responders and non-responders. However, responders had larger amplitude, longer duration and more turns and phases at baseline approaching significance, reflecting more successful urethral reinnervation, than non-responders. CONCLUSIONS: SNM does not alter urethral neuromuscular function 2 weeks post Stage 1 implantation.
AIMS: To characterize the effect of sacral neuromodulation (SNM) on urethral neuromuscular function. METHODS: Following IRB approval, women with refractory overactive bladder (OAB) underwent standardized urethral testing prior to and after Stage 1 SNM implantation. Periurethral sensation was measured using current perception thresholds (CPT). Striated urethral sphincter activity was quantified using concentric needle electromyography (CNE) and Multi-Motor Unit Action Potential (MUP) analysis software. Nonparametric analyses were used to characterize pre/post changes with intervention. Baseline CPT and CNE findings were compared between SNM responders and non-responders. RESULTS: Twenty-seven women were enrolled in this pilot study with a mean age of 61 ± 13 years. Twenty of 26 women (76.9%) responded to SNM and went to Stage 2 permanent implantation. Four (14.8%) withdrew after Stage 1 implantation; three of the four withdrawals had not had therapeutic responses to SNM. CPT and CNE parameters did not significantly differ from baseline 2 weeks after SNM. Pre-SNM urethral sensation was not significantly different between responders and non-responders. However, responders had larger amplitude, longer duration and more turns and phases at baseline approaching significance, reflecting more successful urethral reinnervation, than non-responders. CONCLUSIONS:SNM does not alter urethral neuromuscular function 2 weeks post Stage 1 implantation.
Authors: Lior Lowenstein; Kimberly Kenton; Elizabeth R Mueller; Linda Brubaker; Edmond Sabo; Ramón A Durazo-Arivzu; Mary P Fitzgerald Journal: Int Urol Nephrol Date: 2011-10-13 Impact factor: 2.370
Authors: W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein Journal: World J Urol Date: 2002-11-15 Impact factor: 4.226
Authors: Ranjana Jairam; Jamie Drossaerts; Tom Marcelissen; Gommert van Koeveringe; Desiree Vrijens; Philip van Kerrebroeck Journal: Urol Int Date: 2021-05-31 Impact factor: 1.934
Authors: Jacek K Szymański; Aneta Słabuszewska-Jóźwiak; Kornelia Zaręba; Grzegorz Jakiel Journal: Wideochir Inne Tech Maloinwazyjne Date: 2019-05-23 Impact factor: 1.195